MedTrace Logo

Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction

NCT00574756 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-08-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of ranolazine, an FDA-approved medication for the treatment of angina, on heart function by using echocardiography.

Conditions

  • Ranolazine
  • Diastolic Heart Failure
  • Tissue Doppler Ultrasound
  • Echocardiography

Interventions

DRUG

ranolazine

extended release 500 mg twice a day for two weeks

Sponsors & Collaborators

Principal Investigators

  • Anthony DeMaria, MD · UCSD Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00574756 on ClinicalTrials.gov